Skip to main content

Arrowhead Reports Increased Fiscal Q4 Losses on Higher Expenses


Arrowhead Research this week reported its fiscal fourth-quarter financial results, posting a higher net loss amid increased operating expenses.

The company also said that efforts to integrate its subsidiaries into a single company are underway.

According to Arrowhead, its net loss for the three-month period ended Sept. 30 was $2.8 million, or $0.39 a share, versus a loss of $2 million, or $0.28 per share, in the same period a year before.

Arrowhead recorded revenues of $296,000 in the quarter, versus no revenues a year earlier. However, the company's fourth-quarter operating costs jumped to $2.9 million from $1.8 million last year.

In a statement, Arrowhead President and CEO Christopher Anzalone said that the company is “well underway [toward] integrating our subsidiaries and programs into one cohesive operating company with multiple products and technologies.”

Arrowhead has maintained a strong interest in RNAi through its Calando Pharmaceuticals subsidiary, and it recently acquired the US RNA therapeutic assets of Roche (GSN 10/27/2011). The company also holds a stake in nanomedicines firm Leonardo Biosystems, which has developed a delivery technology with potential in RNAi (GSN 5/20/2010).

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.